Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P628: Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiencesECCO '18 Vienna
Year: 2018
Authors:

K. Szántó1*, K. Farkas1, M. Rutka1, A. Bálint1, R. Bor1, Á. Milassin1, A. Fábián1, Z. Szepes1, F. Nagy1, N. Vass2, D. Szűcs2, T. Molnár1

1University of Szeged, 1st Department of Internal Medicine, Szeged, Hungary, 2University of Szeged, Department of Pediatrics, Szeged, Hungary

P629: Impact of surgical treatment on quality of life in Crohn’s disease: Short-and longer-term follow-upECCO '18 Vienna
Year: 2018
Authors:

S. D'Ugo1,2*, F. Romano2, G. Bagaglini2, L. Fazzolari2, B. Sensi2, A. Di Giorgio2, G. Sica2

1Tor Vergata University, Surgery, Rome, Italy, 2Tor Vergata University, Department of Surgery, Rome, Italy

P630: Development and evaluation of BioCLIA-Tracker infliximab kit: A fast and innovative chemiluminescent assay for the monitoring of patients treated with infliximabECCO '18 Vienna
Year: 2018
Authors:

G. Noguier*, C. Montaillier, L. Colombeau, T. Ticaud, E. Parussini

Theradiag, R&D, Croissy Beaubourg, France

P631: Treatment of established post-operative recurrence of Crohn’s disease with anti-TNF agents: Preliminary data of a multicentre, nationwide studyECCO '18 Vienna
Year: 2018
Authors:

F. Cañete1,2*, M. Mañosa2,3, M. Barreiro-de Acosta4, E. Iglesias5, R. Ríos6, R.C. González-Sueyro7, A. Villoria3,8, M. Navarro-Llavat9, I. Rodriguez-Lago10, C. Taxonera11, P. Navarro12, P. López13, L. Ramos14, M. Van Domselaar15, A. Algaba16, M.J. Casanova3,17, C. Muñoz-Villafranca18, R. Pajares19, M. Sampedro20, M. Rivero21, P.G. Delgado-Guillena22, A. Hernández23, C. Aràjol24, A.F. Pordomingo25, M. Piqueras26, E. Sáinz-Arnau27, O. Benítez-Leiva3,28, P. Ramírez-de la Piscina29, E. Cabré2,3, E. Domènech2,3

1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona - Barcelona, Spain, 2Hospital Universitari Germans Trias i Pujol, Department of Gastroenterology, Badalona - Barcelona, Spain, 3CIBEREHD, Madrid, Spain, 4CHU Santiago, Santiago de Compostela, Spain, 5Hospital Reina Sofía, Cordoba, Spain, 6Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 7Hospital Universitari Clínic, Gastroenterology, Barcelona, Spain, 8Hospital Parc Taulí, Gastroenterology, Sabadell, Spain, 9Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain, 10Hospital de Galdakao, Gastroenterology, Galdakao, Spain, 11Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 12Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain, 13Hospital Universitario Fundación Alcorcón, Gastroenterology, Alcorcón, Spain, 14Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain, 15Hospital Universitario de Torrejón, Gastroenterology, Torrejón de Ardoz, Spain, 16Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain, 17Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 18Hospital Universitario Basurto, Gastroenterology, Bilbao, Spain, 19Hospital Universitario Infanta Sofía, Gastroenterology, San Sebastián de los Reyes, Spain, 20Hospital de Mataró, Gastroenterology, Mataró, Spain, 21Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain, 22Hospital General de Granollers, Gastroenterology, Granollers, Spain, 23Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain, 24Hospital Universitari de Bellvitge; IDIBELL, Gastroenterology, L'Hospitalet del Llobregat, Spain, 25Hospital Universitario de Salamanca, Gastroenterology, Salamanca, Spain, 26Consorci Sanitari de Terrassa, Gastroenterology, Terrassa, Spain, 27Hospital Arnau de Vilanova, Gastroenterology, Lleida, Spain, 28Hospital Universitario Mútua Terrassa, Gastroenterology, Terrassa, Spain, 29Hospital Universitario Araba, Gastroenterology, Vitoria, Spain

P632: Trough levels of golimumab at Week 6 predict drug retention rate in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

S. Stefanovic1*, I. Detrez2, G. Compernolle2, E. Brouwers2, N. Sever1, B. Stabuc1, I. Ferkolj1, N. Smrekar1, G. Novak1, M. Kozelj1, M. Ferrante3, A. Gils2, D. Drobne1

1University Medical Centre Ljubljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia, 2Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

P633: Concordance between endoscopy and histology scores at baseline and following induction therapy with the JAK1 inhibitor filgotinib in active Crohn’s disease: Results from FITZROY studyECCO '18 Vienna
Year: 2018
Authors:

W. Reinisch1*, G. De Hertogh2, G. D'Haens3, W. Li4, A. Serone4, C. Tasset5, A. Van der Aa5, S. Vermeire6

1Medical University of Vienna, Division of Gastroenterology and Hepatology, Vienna, Austria, 2University Hospitals Leuven, Department of Pathology, Leuven, Belgium, 3Academic Medical Centre, Inflammatory Bowel Disease Centre, Amsterdam, The Netherlands, 4Gilead Sciences, Inc., Foster City, USA, 5Galapagos NV, Mechelen, Belgium, 6University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium

P634: Clinical and endoscopic remission with vedolizumab treatment in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

A. Almutairdi, C. Ma*, P.G. Kotze, A. Al-Damarki, S. Devlin, G. Kaplan, C. Seow, K. Novak, C. Lu, J. Ferraz, M. Stewart, M. Buresi, M. Mathivanan, H. Jijon, J. Heatherington, M.-L. Martin, R. Panaccione

University of Calgary, IBD unit, division of Gastroenterology and Hepatology, Calgary, Canada

P635: Real-world treatment persistence and associated costs with biologic therapy in patients with inflammatory bowel disease (IBD): Results of a retrospective cohort analysis of 1,149 patients treated in GermanyECCO '18 Vienna
Year: 2018
Authors:

A. Groth1, T. Wilke2, A. Brandes3*, B. Ratsch3, A. Fuchs4, B. Deiters5, B. Bokemeyer6

1IPAM e.V., Wismar, Germany, 2Ingress Health HWM GmbH, Wismar, Germany, 3Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany, 4AOK Plus, Dresden, Germany, 5GWQ Serviceplus AG, Düsseldorf, Germany, 6Gastroenterologische Gemeinschaftspraxis Minden, Minden, Germany

P636: Long-term outcome of anti-tumour necrosis factor treatment in inflammatory bowel disease: A real-life observational study at Østfold Central Hospital, NorwayECCO '18 Vienna
Year: 2018
Authors:

F. Lerang1*, E. Gunther2, M. Henriksen1, L.-P. Jelsness-Jørgensen1,3

1Central Hospital of Østfold, Medical, Sarpsborg, Norway, 2Nedre Glommen Legegruppe, Medical, Fredrikstad, Norway, 3Østfold University College, Fredrikstad, Norway

P637: High faecal and serum tumour necrosis factor-α levels are associated with non-response to infliximab in patients with ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

H. Meringer1,2,3*, N. Maharshak1,2,3, Y. Ron1,3, H. Yanai1,3,4, S. Cohen-Kedar1,2,3,4, I. Dotan1,2,3,4

1Tel Aviv Sourasky Medical Center, Inflammatory Bowel Diseases Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 2Tel Aviv Sourasky Medical Center, Research Center for Digestive Tract and Liver Diseases, Tel Aviv, Israel, 3Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel, 4Current: Rabin Medical Center, Department of Gastroenterology, Petach Tikva, Israel

P638: Nutritional status in paediatric Crohn’s disease patients: Does exclusive enteral nutrition help?ECCO '18 Vienna
Year: 2018
Authors:

C. Strisciuglio1*, E. Scarpato2, M.R. Serra2, F.P. Giugliano2, S. Cenni2, C. Mainolfi3, M. Martinelli2, E. Miele2

1University of the Campania “Luigi Vanvitelli”, Department of Woman, Child and General and Specialized Surgery, Naples, Italy, 2University of Naples “Federico II”, Department of Translational Medical Science, Section of Pediatrics, Naples, Italy, 3University of Naples “Federico II”, Department of Radiology, Naples, Italy

P639: Validation of the Quantum Blue® infliximab-level rapid test in clinical practice of patients with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Strik1*, T. Schuster2, M. Löwenberg1, C. Ponsioen1, G. D'Haens1

1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2Buhlmann Laboratories, Schönenbuch, Switzerland

P640: Risk of post-operative complications among Crohn’s disease patients treated pre-operatively with vedolizumab. A matched case–control studyECCO '18 Vienna
Year: 2018
Authors:

J.Y. Kim1, K. Zaghiyan2, P. Fleshner2*

1Hallym University College of Medicine, Dongtan Sacred Hospital, Department of Surgery, KyungKee, Seoul, South Korea, 2Cedars-Sinai Medical Center, Division of Colorectal Surgery, Los Angeles, USA

P641: Comparison of rectal and oral mesalazine for treatment of rectal ulcerative proctitis: A prospective randomised clinical trial (CORRECT study)ECCO '18 Vienna
Year: 2018
Authors:

S. Kato1*, K. Kani1, H. Kurihara2, T. Ohmori3, K. Yakabi1

1Saitama Medical Center, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe City, Saitama, Japan, 2Tokorozawa Proctology Hospital, Tokorozawa, City, Saitama, Japan, 3Ohmori Toshihide Gastrointestinal Clinic, Ageo City, Saitama, Japan

P642: Adaptive dosing during infliximab induction therapy can improve mucosal healing rates in patients with ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

E. Dreesen1*, R. Faelens1, G. Van Assche2,3, M. Ferrante2,3, S. Vermeire2,3, A. Gils1, T. Bouillon1

1KU Leuven, Departement of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

P643: Filgotinib decreases systemic and mucosal markers of inflammation that are associated with endoscopic improvement in moderately to severely active Crohn’s disease patientsECCO '18 Vienna
Year: 2018
Authors:

X. Roblin1*, G. D'Haens2, R. Galien3, L. Goyal4, W. Li4, A. Mirza4, A. Serone4, C. Tasset5, A. Van der Aa5, J. Woo4, S. Vermeire6

1University Hospital, Saint-Etienne, France, 2Academic Medical Centre, Amsterdam, The Netherlands, 3Galapagos SASU, Romanville, France, 4Gilead Sciences, Foster City, USA, 5Galapagos NV, Mechelen, Belgium, 6University Hospitals Leuven, Leuven, Belgium

P644: Effectiveness of vedolizumab on intestinal outcomes and articular manifestations: Real-world data from the Sicilian Network for inflammatory bowel disease (SN-IBD)ECCO '18 Vienna
Year: 2018
Authors:

F.S. Macaluso1*, R. Orlando1, W. Fries2, M. Scolaro2, A. Magnano3, D. Pluchino3, M. Cappello4, G.C. Morreale4, S. Siringo5, A.C. Privitera6, C. Ferracane6, N. Belluardo7, N. Alberghina7, M. Ventimiglia1, G. Rizzuto1, S. Renna1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

1Division of Internal Medicine, ''Villa Sofia-Cervello'' Hospital, Palermo, Italy, 2Inflammatory Bowel Disease Unit, A.O.U. Policlinico "G. Martino”, Messina, Italy, 3Gastroenterology Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy, 4Gastroenterology and Hepatology Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy, 5Gastroenterology Unit, A.R.N.A.S. “Garibaldi”, Catania, Italy, 6IBD Unit, A.O. "Cannizzaro”, Catania, Italy, 7Gastroenterology Unit, A.O. “Guzzardi”, Vittoria, Italy

P645: Dynamics of proinflammatory cytokines in patients with Crohn's disease who received combined therapy with mesenchymal stromal cells of bone marrow and azathioprineECCO '18 Vienna
Year: 2018
Authors:

O. Knyazev, N. Fadeeva*, A. Babayan, E. Dobroluybova, I. Donchenko

Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation

P646: Refinement of surgical technique offsets increased severity of Crohn’s disease and co-morbidities to maintain low post-operative morbidityECCO '18 Vienna
Year: 2018
Authors:

D. Mege1,2*, K. Garrett1, J. Milsom1, T. Sonoda1, F. Michelassi1

1New York Presbyterian Hospital, New York, USA, 2Aix-Marseille University, Marseille, France

P647: Is liver steatosis a risk factor for hepatotoxicity in patients with inflammatory bowel disease on thiopruines?ECCO '18 Vienna
Year: 2018
Authors:

J. Phillips1, R. Preskey2*, C. Penfold3, J. Tyrrell-Price1, F. Gordon4

1Bristol Royal Infirmary, Department of Gastroenterology, Bristol, UK, 2Bristol Royal Infirmary, Bristol, UK, 3University of Bristol, School of Clinical Sciences, Bristol, UK, 4Bristol Royal Infirmary, Department of Hepatology, Bristol, UK